Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10283677 | 0.80 | KMT2A (0.47) | CYP2D6CYP2C9MAPK1CYP2C19KMT2A | |
| SCHEMBL6365121 | 0.80 | KMT2A (0.47) | CYP2D6CYP2C9MAPK1CYP2C19KMT2A | |
| SCHEMBL6468219 | 0.80 | KMT2A (0.47) | CYP2D6CYP2C9MAPK1CYP2C19KMT2A | |
| SCHEMBL30938102 | 0.74 | CYP2D6 (0.38) | CYP2D6CYP2C9MAPK1CYP2C19KMT2A | |
| SCHEMBL20206928 | 0.73 | CHRM2 (0.37) | MAPK1ALDH1A1 | |
| SCHEMBL21371627 | 0.73 | SMN1; SMN2 (0.49) | KMT2ASMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL21371628 | 0.73 | SMN1; SMN2 (0.49) | KMT2ASMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL761306 | 0.73 | SMN1; SMN2 (0.49) | KMT2ASMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL15125072 | 0.73 | CHRNB2 (0.50) | CYP2D6CYP2C9MAPK1CYP2C19KMT2A | |
| SCHEMBL14144133 | 0.72 | HDAC4 (0.42) | CYP2D6CYP2C9CYP2C19ALDH1A1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766442-B2 | T-cell lymphoma treatments | CITY OF HOPE (US) | 2023-09-26 | — | — | US | disclosed |
| US-11230560-B2 | Synthesis of ETP derivatives | CITY OF HOPE (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210145840-A1 | T-CELL LYMPHOMA TREATMENTS | CITY OF HOPE | 2021-05-20 | — | — | US | disclosed |
| US-20200277307-A1 | SYNTHESIS OF ETP DERIVATIVES | CITY OF HOPE | 2020-09-03 | — | — | US | disclosed |
| EP-2909214-B1 | ETP DERIVATIVES | HOPE CITY (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10246471-B2 | ETP derivatives | CITY OF HOPE (US) | 2019-04-02 | — | — | US | disclosed |
| CN-108440571-A | Etp derivatives | 希望之城 | 2018-08-24 | — | — | CN | disclosed |
| US-20180155367-A1 | ETP DERIVATIVES | CITY OF HOPE | 2018-06-07 | — | — | US | disclosed |
| US-20180155367-A1 | ETP DERIVATIVES | CITY OF HOPE | 2018-06-07 | — | — | US | disclosed |
| CN-104870452-B | Etp derivatives | 希望之城 | 2018-04-13 | — | — | CN | disclosed |
| US-9856273-B2 | ETP derivatives | CITY OF HOPE (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170037058-A1 | ETP DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-09 | — | — | US | disclosed |
| US-20170037058-A1 | ETP DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-09 | — | — | US | disclosed |
| US-9527868-B2 | ETP derivatives | CITY OF HOPE (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527868-B2 | ETP derivatives | CITY OF HOPE (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150291622-A1 | ETP DERIVATIVES | CITY OF HOPE | 2015-10-15 | — | — | US | disclosed |
| US-20150291622-A1 | ETP DERIVATIVES | CITY OF HOPE | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277307-A1 | SYNTHESIS OF ETP DERIVATIVES | ETV6, SQOR, TXN | CYP2D6 780/4885CYP2C9 1051/4885MAPK1 3428/4885 |
| US-10246471-B2 | ETP derivatives | ETV6, ETV1, ELP1 | CYP2D6 725/4885CYP2C9 1977/4885MAPK1 4319/4885 |
| US-20150291622-A1 | ETP DERIVATIVES | ETV6, ETV1, ELP1 | CYP2D6 725/4885CYP2C9 1977/4885MAPK1 4319/4885 |
| US-11230560-B2 | Synthesis of ETP derivatives | ETV6, SQOR, ETFA | CYP2D6 230/4885CYP2C9 375/4885MAPK1 3406/4885 |
| US-20170037058-A1 | ETP DERIVATIVES | ETV6, ETV1, ELP1 | CYP2D6 725/4885CYP2C9 1977/4885MAPK1 4319/4885 |
| US-11766442-B2 | T-cell lymphoma treatments | MALT1, BCL6, BCL3 | CYP2D6 3140/4885CYP2C9 3865/4885MAPK1 4227/4885 |
| US-20210145840-A1 | T-CELL LYMPHOMA TREATMENTS | MALT1, BCL6, BCL3 | CYP2D6 3140/4885CYP2C9 3865/4885MAPK1 4227/4885 |
| US-20180155367-A1 | ETP DERIVATIVES | ETV6, ETV1, ELP1 | CYP2D6 725/4885CYP2C9 1977/4885MAPK1 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.